Hydromorphone

Verify with FDA CVM →

832 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
832
Total Reports
135
Deaths Reported
1620.0%
Death Rate

Active Ingredients

Hydromorphone

Administration Routes

UnknownIntramuscularIntravenousParenteralSubcutaneousOralOtherEpiduralIntra-Articular

Species Affected

Dog 620
Cat 200
Rabbit 4
Goat 2
Other Reptiles 1
Lizard 1
Other Bovine 1
Cougar 1
Pig 1
Unknown 1

Most Affected Breeds

Domestic Shorthair 114
Retriever - Labrador 89
Dog (unknown) 61
Crossbred Canine/dog 39
Cat (unknown) 28
Chihuahua 21
Retriever - Golden 21
Pit Bull 20
Domestic Longhair 19
Unknown 17

Most Reported Reactions

Vomiting 98
Death 75
Not eating 73
Lethargy (see also Central nervous system depression in 'Neurological') 69
Other abnormal test result NOS 61
Lack of efficacy - NOS 60
Anorexia 55
Death by euthanasia 53
Injection site swelling 52
Tachycardia 51
Decreased appetite 45
Lethargy (see also Central nervous system depression in Neurological) 44

Outcome Breakdown

Recovered/Normal
380 (45.6%)
Outcome Unknown
174 (20.9%)
Ongoing
137 (16.4%)
Died
82 (9.8%)
Euthanized
54 (6.5%)
Recovered with Sequela
7 (0.8%)

Data Summary

Metric Value
Total adverse event reports 832
Reports involving death 135
Case-fatality rate (reported events) 1620.0%
Distinct species in reports 10
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Hydromorphone Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 832 adverse event reports referencing Hydromorphone, including 135 reports in which the animal died — a 1620.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Hydromorphone. Reported administration routes include Unknown, Intramuscular, Intravenous, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Hydromorphone reports are Dog (620 reports), Cat (200 reports), Rabbit (4 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (114), Retriever - Labrador (89), Dog (unknown) (61) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Hydromorphone are Vomiting (98), Death (75), Not eating (73), Lethargy (see also Central nervous system depression in 'Neurological') (69). Of the 834 reports with a coded outcome, Recovered/Normal is the leading category at 45.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Hydromorphone.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial